Learning, Inspiring, Sharing
Physicians who wish to apply for a waiver to prescribe buprenorphine for the treatment of opioid use disorders.
At the conclusion of this activity, learners should be able to:
- Review addiction identification and evidence-based treatments.
- Discuss the pharmacology of opioids as it relates to treatment of opioid use disorder (OUD) patients.
- Describe the fundamentals of office-based opioid treatment including the treatment of the co-morbid patient.
- Explain the process of buprenorphine induction as well as stabilization and maintenance.
- Discuss other approved antagonist and agonist medications to treat OUD.
- Discuss basic office protocols including medical record documentation and confidentially.
- Utilize evidence-based resources to ensure providers have the confidence to prescribe buprenorphine for patients with OUD.
- Apply for a MAT Waiver Training Certificate to begin treating patients with OUD.
Fee: No cost
Accreditation Statement: The American Academy of Addiction Psychiatry (AAAP) is accredited by the ACCME to provide continuing medical education for physicians.
Designation Statement: American Academy of Addiction Psychiatry (AAAP) designates this enduring material for a maximum of 8 (eight) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation Release Date: November 30, 2018
Accreditation Expiration Date: November 30, 2021
Method of participation in the activity: To be awarded a maximum of 8 AMA PRA Category 1 Credits™ and a MAT Waiver Training Certificate you must:
- Review 8 training modules (8 hours) provided in this activity.
- Earn a minimum cumulative score of 75% on the examination. Participants will have three opportunities to correctly answer the examination.
- Complete a final evaluation and follow instructions at the end of the course regarding how to retrieve your Certificate of Completion as well as a CME Credit Certificate*.
*Credit will not be awarded unless all components of the program are completed. Partial credit will not be awarded.
AAAP's CME program aims to provide educational information that is balanced, independent, objective and free of bias and based on evidence. During the planning process, anyone that is involved in the content is required to disclose to AAAP and our learners any real or potential conflict of interest related to the educational activity. The following individuals have no relevant financial relationships with an ACCME defined commercial interest to disclose: Thomas Penders, MD, Michael Goedde, MD, Nitigna Desai, MD, Karen Oliver, PhD, John renner, Jr, MD, Kevin Sevarino, MD, PhD, Stephen Wyatt, MD, Sanchit Maruti, MD, Colleen LaBelle, MSN, RN-BC, CARN, Yngvild Olsen, MD, Kathryn Cates-Wessel, Miriam Giles, Erin Waters, Seth Acton, and Justina Pereira.
Disclosure of Unlabeled Medication Use:
Faculty have been advised that any recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. AAAP has determined that all scientific research referred to, reported, or used in ths course conforms to the generally accepted standards of experimental design, data collection, and analysis.
Support for the Program:
Funding for this initiative was made possible (in part) by grant no. 5U79TI026556-03 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.